Rifampicin resistant Mycobacterium tuberculosis in Vietnam, 2020-2022.
Van Nguyen H., Binh Nguyen H., Thu Ha D., Thi Huong D., Ngoc Trung V., Thi Thuy Ngoc K., Huyen Trang T., Vu Thi Ngoc H., Trinh Thi Bich T., Le Pham Tien T., Nguyen Hong H., Phan Trieu P., Kim Lan L., Lan K., Ngoc Hue N., Thi Le Huong N., Le Thi Ngoc Thao T., Le Quang N., Do Dang Anh T., Hữu Lân N., Van Vinh T., Thi Minh Ha D., Thuong Dat P., Phuc Hai N., Crook DW., Thuy Thuong Thuong N., Viet Nguyen N., Thwaites GE., Walker TM.
OBJECTIVE: We conducted a descriptive analysis of multi-drug resistant tuberculosis (MDR-TB) in Vietnam's two largest cities, Hanoi and Ho Chi Minh city. METHODS: All patients with rifampicin resistant tuberculosis were recruited from Hanoi and surrounding provinces between 2020 and 2022. Additional patients were recruited from Ho Chi Minh city over the same time period. Demographic data were recorded from all patients, and samples collected, cultured, whole genome sequenced and analysed for drug resistance mutations. Genomic susceptibility predictions were made on the basis of the World Health Organization's catalogue of mutations in Mycobacterium tuberculosis associated with drug resistance, version 2. Comparisons were made against phenotypic drug susceptibility test results where these were available. Multivariable logistic regression was used to assess risk factors for previous episodes of tuberculosis. RESULTS: 233/265 sequenced isolates were of sufficient quality for analysis, 146 (63 %) from Ho Chi Minh City and 87 (37 %) from Hanoi. 198 (85 %) were lineage 2, 20 (9 %) were lineage 4, and 15 (6 %) were lineage 1. 17/211 (8 %) for whom HIV status was known were infected, and 109/214 (51 %) patients had had a previous episode of tuberculosis. The main risk factor for a previous episode was HIV infection (odds ratio 5.1 (95 % confidence interval 1.3-20.0); p = 0.021). Sensitivity for predicting first-line drug resistance from whole genome sequencing data was over 90 %, with the exception of pyrazinamide (85 %). For moxifloxacin and amikacin it was 50 % or less. Among rifampicin-resistant isolates, prevalence of resistance to each non-first-line drug was